demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
Extensive stage SCLC (Es-SCLC)
Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
Immune checkpoint association
durvalumab plus tremelimumab
durvalumab plus tremelimumab plus SoC CASPIAN ...